Who is sponsoring NCT03908073?

NCT03908073 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT03908073?

Interventions in NCT03908073: Transcutaneous vagal nerve stimulation.

What condition does NCT03908073 study?

NCT03908073 studies Ulcerative Colitis, Vagal Nerve Stimulation, Transcutaneous Vagal Nerve Stimulation.

Is NCT03908073 still recruiting?

NCT03908073 is currently terminated. Last updated 22 March 2022.

Last reviewed 2022-03-22 · How we verify

NCT03908073: EVASION-UC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electrical Vagal Nerve Stimulation in Ulcerative Colitis

Terminated NA Last updated 22 March 2022

What this trial tests

NA trial testing Transcutaneous vagal nerve stimulation in Ulcerative Colitis in 12 participants. Terminated before completion.

Timeline

30 October 2018

Primary endpoint
15 March 2021

15 March 2021

Quick facts

Lead sponsor	Queen Mary University of London
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	12
Start date	30 October 2018
Primary completion	15 March 2021
Estimated completion	15 March 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Transcutaneous vagal nerve stimulation

Conditions studied

Ulcerative Colitis — all drugs for Ulcerative Colitis →
Vagal Nerve Stimulation — all drugs for Vagal Nerve Stimulation →
Transcutaneous Vagal Nerve Stimulation — all drugs for Transcutaneous Vagal Nerve Stimulation →

Sponsor

Queen Mary University of London

Who can join

Adults 18 to 76, any sex, with Ulcerative Colitis or Vagal Nerve Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are approximately 2.5-3 million patients with inflammatory bowel disease (IBD) across Europe, with associated healthcare costs of €4.6-5.6 billion per annum (1). IBD is associated with a significant reduction in quality of life. Treatments directed towards modifying the inflammatory response, such as anti-tumour necrosis factor-alpha (TNF-α) agents, are expensive, can necessitate admission to hospital for their administration and can be associated with side effects (2 3). Thus, the development of a novel non-pharmacological anti-inflammatory intervention, such as electrical vagal nerve stimulation, is warranted. This is a proof of concept study which aims to investigate whether transcutaneous vagal nerve stimulation is effective at reducing stress induced inflammatory cytokine levels in patients with quiescent ulcerative colitis.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases.
Bonaz B, Sinniger V, Pellissier S. · · 2021 · cited 108× · PMID 33828455 · DOI 10.3389/fnins.2021.650971
Anatomical and clinical implications of vagal modulation of the spleen.
Bassi GS, Kanashiro A, Coimbra NC, Terrando N, et al · · 2020 · cited 59× · PMID 32061636 · DOI 10.1016/j.neubiorev.2020.02.011
Neuro-Immune Circuits Regulate Immune Responses in Tissues and Organ Homeostasis.
Jakob MO, Murugan S, Klose CSN. · · 2020 · cited 54× · PMID 32265899 · DOI 10.3389/fimmu.2020.00308
Cholinergic immunomodulation in inflammatory bowel diseases.
Serafini MA, Paz AH, Nunes NS. · · 2022 · cited 16× · PMID 34977822 · DOI 10.1016/j.bbih.2021.100401
Effects of Stress, Vagal Nerve Stimulation and Disease Activity on Circulating Cytokines, Quantified by an Ultrasensitive Technique, in Ulcerative Colitis: A Pilot Study.
Mogilevski T, Hardy MY, Takahashi K, Smith R, et al · · 2025 · cited 1× · PMID 40584280 · DOI 10.1002/jgh3.70206
Macrophages as central mediators of sympathetic neuro-immune interplay in autoimmunity.
Muntjewerff EM, Josyula VS, Lehmair F, Christoffersson G. · · 2025 · PMID 41476959 · DOI 10.3389/fimmu.2025.1654382

Verify or expand the search:

Other trials of Transcutaneous vagal nerve stimulation

Trials testing the same drug.

NCT05899413 — Examining Transcutaneous Vagal Nerve Stimulation as a Facilitator of Social Bonding · completed
NCT05180981 — Imaging Brain Fluids During Breathing · NA · recruiting
NCT04070547 — The Effect of Transcutaneous Vagus Nerve Stimulation on Cognitive Function · NA · completed
NCT03359902 — Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation · NA · completed

Other recruiting trials for Ulcerative Colitis

Currently open trials in the same condition.

NCT07185009 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07265570 — Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184996 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03908073 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 22 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03908073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing